Enveric Biosciences (ENVB) Total Debt (2010 - 2021)
Enveric Biosciences (ENVB) posted Total Debt of $148604.0 for Q2 2021, down 92.08% sequentially from $1.9 million in Q3 2020, and down 94.03% YoY from $2.5 million in Q2 2020.
Enveric Biosciences (ENVB) Total Debt (2010 - 2021) Analysis & Trends
Enveric Biosciences has reported Total Debt for 9 years, with the latest figure at $148604.0 in Q2 2021.
- Quarterly Total Debt fell 94.03% year-over-year to $148604.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $148604.0 (down 94.03% YoY) and the FY2019 annual result came in at $22409.0, up 247.43% from the prior year.
- Total Debt eased to $148604.0 in Q2 2021 per ENVB's latest filing, from $1.9 million in the prior quarter.
- Over five years, Total Debt peaked at $5.2 million in Q4 2017 and troughed at $6450.0 in Q4 2018.
- A 5-year average of $2.8 million and a median of $3.3 million in 2018 frame the typical range for Total Debt.
- The sharpest annual moves came in 2017 and 2018: Total Debt jumped 895.99% in 2017, then slumped 99.88% in 2018.
- Over 5 years, Total Debt stood at $5.2 million in 2017, then plunged by 99.88% to $6450.0 in 2018, then soared by 247.43% to $22409.0 in 2019, then jumped by 8274.21% to $1.9 million in 2020, then sank by 92.08% to $148604.0 in 2021.
- According to Business Quant data, Total Debt over the past three periods registered $148604.0, $1.9 million, and $2.5 million for Q2 2021, Q3 2020, and Q2 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 9.34 Bn |
| 10 | Enveric Biosciences | 5.72 Mn | -2.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 148,604.00 |
| Sep 30, 2020 | 1.88 Mn |
| Jun 30, 2020 | 2.49 Mn |
| Mar 31, 2020 | 4.55 Mn |
| Dec 31, 2019 | 22,409.00 |
| Sep 30, 2019 | 3.43 Mn |
| Mar 31, 2019 | 4.19 Mn |
| Dec 31, 2018 | 6,450.00 |
| Sep 30, 2018 | 3.60 Mn |
| Jun 30, 2018 | 3.27 Mn |
| Mar 31, 2018 | 4.29 Mn |
| Dec 31, 2017 | 5.18 Mn |
| Sep 30, 2017 | 1.98 Mn |
| Jun 30, 2017 | 1.74 Mn |
| Mar 31, 2017 | 4.98 Mn |
| Dec 31, 2016 | 4.63 Mn |
| Sep 30, 2016 | 1.57 Mn |
| Jun 30, 2016 | 5.50 Mn |
| Mar 31, 2016 | 500,000.00 |
| Dec 31, 2015 | 6.24 Mn |